Yale Researcher Named HHMI Investigator

Category: General Health News
Monday, October 15, 2007 at 2:51:31 PM
 Font Size 
Erol Fikrig, M.D., a Yale School of Medicine researcher who specializes in the study and treatment of Lyme disease, West Nile virus, and other vector-borne diseases, has been named a Howard Hughes Medical Institute (HHMI) investigator.


HHMI is a non-profit medical research organization that invests in the support, training, and education of the nation’s most creative and promising scientists. Its investigators are chosen through rigorous national competitions. The organization was founded in 1953 by aviator and industrialist Howard R. Hughes.

Fikrig, the Waldemar Von Zedtwitz Professor of Medicine, also studies human granulocytic ehrlichiosis, a newly described pathogen transmitted by ticks. His research focuses on molecular strategies the biological agent uses to survive in white blood cells.

“Erol Fikrig is an outstanding scientist who studies the important interactions between tick-borne bacteria and their vector hosts,” said Robert Alpern, M.D., dean of the medical school. “These are important scientific and medical issues, the understanding of which will save lives.”

Fikrig’s research has led to a new understanding of the relationship between the pathogens that transmit the diseases, the vectors (i.e. organisms) that carry the pathogens, and the hosts they infect. Information from his studies is suggesting new strategies to prevent and treat Lyme disease, West Nile encephalitis, and other infections, by interrupting these relationships.

His first project after coming to Yale in 1988 was developing and testing a Lyme disease vaccine with HHMI investigator Richard Flavell, chair of the Department of Immunobiology and who remains a frequent collaborator. While the vaccine was being developed, Fikrig made the first of a series of important discoveries about the life cycle of the bacterium. He demonstrated that, in moving between the tick and humans, the bacterium covers itself with a protein drawn from the tick’s saliva. That protein helps the bacterium avoid attack by the human immune system.
Page 1 Page 1 | 2  Next
       Email Email      RSS Feeds RSS Feeds      Print this page Print      Save this page Save      Link Link      Syndicate Syndicate      Comments Comments
  
Comment & Contribute
* Your comment can be maximum of 2500 characters
Notify me when reply is posted   

Kathleen M. Dickson

10/15/2007

Erol Fikrig is a criminal. Four days after applying for the patent for LYMERix, Yale's fake vaccine which came off the market due to the unreported vaccine adverse events which were reported by the public and in two class action lawsuits against the manufacturer, SmithKline, Erol Fikrig and Richard Flavell published about how it, OspA or LYMErix, would not work as a vaccine. That is because Lyme is just a relaping fever, a disease for which there can be no vaccine, since antibodies are rendered useless due to antigenic variation. This is a joke on the world. Fikrig is a criminal. Kathleen M. Dickson http://www.actionlyme.org
Reply | Forward

General News

.
Supply of Additional Private Services on the Rise
.
South Korea To Buy Flu Vaccines For Quarter Of Population
.
China Apologizes to Mexico for Tough Swine Flu Stand
.
Movie Encourages Teens To Take Up Smoking Regardless Of Character
Read More

Related Links

Medindia on Lyme disease DNA detection
The diagnosis of Lyme disease is difficult by serological tests but detected by DNA based tests. This tests is a valuable diagnostic tool for detection of Lyme disease.

Read More...

For More Information
West Nile Virus Can Be Tackled By New Strategy
500 + Health news categories
Latest Health News From Leading Resources
Updated every 30 minutes
Latest Headlines
WHO Says Access to Swine Flu Vaccine a 'critical Question' (3 hrs ago)
Memory Decline in Alzheimer's Mice Set Right by Human Blood Stem Cell Growth Factor (3 hrs ago)
Scientists Identify Why H1N1 Flu Spreads from Person to Person Less Effectively Than Other Flu Viruses (3 hrs ago)
PET can Measure Effectiveness of Novel Breast Cancer Treatment, Study Says (3 hrs ago)
Supply of Additional Private Services on the Rise (3 hrs ago)
Increased Research Output Seen in Developing Countries (3 hrs ago)
Call for Public Debates on Future Uses of Stem Cells (3 hrs ago)
All Latest News
Popular News Topics
News Archive
Date :
Category :
Keyword :
Medindia Special Reports
multiple-sclerosis-day.jpg
krishnaraman.jpg
incest-daughters.jpg
world-hepatitis-day-2009.jpg
swine-flu.jpg
Web Medindia  Advanced Search
Feedback
Last Updated - - Designed & Content Managed by Medindia Health Network Pvt Ltd. Hosted & Technical Support by FrontPoint Systems
DisclaimerThe contents of this site are for informational purposes only. Always seek the advice of a qualified physician for any doubts.
To Read full Disclaimer Click Here!
Best viewed with resolution 1024x768 px.
Advertise with us |  Medindia Copyright |  Privacy Policy |  © All Rights Reserved 1997 - 2009